Company

Partner

Amount (US$M)

Details

Date

Total: $105M (Year total: $947.8M)

Aveo Oncology Inc. (Cambridge, Mass.)

EUSA Pharma Ltd. (Hemel Hempstead, U.K.)

$2.00

$2M milestone payment following the commercial launch and reimbursement in Germany of Fotivda (tivozanib) as a first-line treatment of adult patients with advanced renal cell carcinoma

11/20/18

Bioarctic AB (Stockholm)

Abbvie Inc. (North Chicago)

$50.00

$50M following Abbvie's decision to exercise an option on its preclinical alpha-synuclein antibody program

11/5/18

Cytori Therapeutics Inc. (San Diego)

Bimini Technologies LLC (San Diego)

$1.00

$1M upon Bimini's achievement of the first $10M in gross profits for previous divestiture of the Puregraft product line

11/1/18

Exelixis Inc. (Alameda, Calif.)

Ipsen SA (Paris)

$40.00

Ipsen received European Commission approval to market Cabometyx as a monotherapy for HCC in adults who have previously been treated with sorafenib; triggers $40M milestone payment to Exelixis

11/15/18

Vedanta Biosciences Inc. (Cambridge, Mass.)

Janssen Research & Development LLC (unit of Johnson & Johnson; New Brunswick, N.J.)

$12.00

$12M triggered by the start of a phase I trial of VE-202

11/28/18

Vernalis Research (Cambridge, U.K.; subsidiary of Ligand Pharmaceuticals Inc.)

Daiichi Sankyo Co. Ltd. (Tokyo)

N/A

Multiple milestone payments under its drug discovery collaboration with Daiichi; the research is using Vernalis' fragment and structure-based drug discovery platform for work on two undisclosed oncology targets

11/14/18


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

No Comments